Business
aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies
Panel discussion to be held on Saturday, March 25 at 12:00pm ET / 11:00am CT / 9:00am PT. SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.
About this update from Atyr Pharma, Inc.
[{"type":"text","content":"Panel discussion to be held on Saturday, March 25 at 12:00pm ET / 11:00am CT / 9:00am PT.\nSAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, and the Foundation for Sarcoidosis Research (FSR), the leading international nonprofit organization dedicated to finding a cure for sarcoidosis and improving care for sarcoidosis patients, today announced that they will hold a Virtual Town Hall on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies. The event will be held on Saturday, March 25, 2023, at 12:00pm ET / 11:00am CT / 9:00am PT. The Town Hall discussion will feature a panel of leading experts related to sarcoidosis treatment and advocacy, including: John Carlin (Moderator) – Host, Sarc Fighter Podcast and Co-Chair, FSR Patient Advisory CommitteeJim Kuhn – FSR Patient Advocate for SarcoidosisShambhu Aryal, M.D. – Medical Director, Inova Lung Transplant Program and Inova Sarcoidosis Center, Inova Fairfax HospitalMary McGowan – CEO, FSRSanjay S. Shukla, M.D., M.S. – President and CEO, aTyr Pharma Registration is open to anyone who wishes to attend. For more information and to register, please visit the event page on the FSR website here. Following the event, a replay will be available on the FSR YouTube Channel. “We look forward to this discussion to help educate patients on evaluating sarcoidosis treatments and considerations for transitioning to a new therapy. While steroids are a treatment option for many people with sarcoidosis, they have limited efficacy and serious side effects when used long term,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “New non-steroidal treatments that are safe and can help patients maintain adequate symptom control while improving quality of life are on the horizon. Efzofitimod is currently in clinical development for pulmonary sarcoidosis and may in the future provide a better alternative to steroid treatment.” “In advance of Sarcoidosis Awareness Month in April, we are pleased to collaborate with aTyr and other members of our esteemed panel for this important event to discuss new and emerging treatment options for sarcoidosis and what to expect when ...